We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Sampling Compared for Leishmaniasis Rapid Test

By LabMedica International staff writers
Posted on 11 Jul 2013
Antibody-detecting rapid diagnostic tests (RDTs) are available to aid in the diagnosis of visceral leishmaniasis (VL), the second most fatal parasitic disease after malaria. More...


Although these RDTs have been developed, validated, and approved for use with serum, they are universally performed using whole blood and therefore it was deemed necessary to determine whether an established RDT is as sensitive on whole blood as on serum.

Tropical medicine specialists at McGill University (Montreal, QC, Canada) working with colleagues at the Rajendra Memorial Research Institute of Medical Sciences (Patna, India) compared serum and blood samples from 624 individuals with symptoms of VL attending the outpatient clinic. They used the rK39 immunochromatographic RDT to assess and evaluate the blood and serum samples from each patient. The test was considered positive when both the control line and the test line appeared red in color.

The rK39 Kalazar Detect RTD (InBios International; USA; Seattle, WA, USA) detected 251 cases who were seropositive on both blood and serum sample. In comparison, 334 were negative on both serum and blood. Notably, there were 26 cases that were negative on blood and positive on serum. These 26 individuals in general had low titer antibodies against rK39 as determined by an enzyme linked immunosorbent assay (ELISA) and follow-up on most of these individuals revealed none had persistent VL symptoms. There were 13 cases that were positive on blood and negative on serum and these were considered to be false positives.

The authors concluded that the major observation from their study was that the concordance of the rK39 RDT performed on serum versus blood was excellent. The test can however be negative on blood and positive on serum when the titer of anti-K39 antibodies is low. We therefore recommend that when an individual from an endemic area has clinical symptoms of VL and the blood rK39 RDT is negative, that the test should be redone two to three weeks later if the symptoms persist since during this interval the titer may increase if the disease begins to progress. The study was published on May 23, 2013, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:
McGill University
Rajendra Memorial Research Institute of Medical Sciences
InBios International


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Ultrasonic Cleaner
UC 300 Series
New
FOB+Transferrin+Calprotectin+Lactoferrin Test
CerTest FOB+Transferrin+Calprotectin+Lactoferrin Combo Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Pathology

view channel
Image: AI-analyzed images from the FDM microscope show platelet clumps in motion (Photo courtesy of Hirose et al CC-BY-ND)

AI Microscope Spots Deadly Blood Clots Before They Strike

Platelets are small blood cells that act as emergency responders in the body, rushing to areas of injury to help stop bleeding by forming clots. However, sometimes platelets can overreact, leading to complications.... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.